Letter to the Editor Regarding the “Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The Constant Analysis” Article [Letter]

摘要

In a recent edition of Clinical Ophthalmology, Zarranz-Ventura and Mali presented1an area-under-the-curve (AUC) analysis that directly compared the best correctedvisual acuity (BCVA) improvements in the pivotal diabetic macular edema (DME)trials (FAME and MEAD) for the fluocinolone acetonide implant (Iluvien) and thedexamethasone implant (Ozurdex). They concluded that patients in FAME hadsuperior BCVA improvement over the course of 36 months. We contend that thisanalysis and the resultant conclusions are flawed because of methodologic deficiencies in the MEAD trial.